MiNK Therapeutics Inc (INKT) showcases significant advancements in cell therapy while navigating financial hurdles and planning for future growth.

Third Quarter Net Sales and Adjusted EBITDA Exceeded Guidance Driven by 44% OEM Growth Gross Margin Expanded 710 Basis Points Year-over-Year ...

Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license ...